Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma
- Conditions
- Asthma
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00232999
- Locations
- 🇨🇦
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
🇨🇦Centre de cardiology et de pneumologie de l'Universite Laval, Sainte-Foy (Quebec City), Quebec, Canada
🇨🇦University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
- Conditions
- Relapse Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00203099
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 208
- Registration Number
- NCT00203021
- Locations
- 🇺🇸
Teva Investigational Site 009, Los Angeles, California, United States
🇺🇸Teva Investigational Site 004, Los Angeles, California, United States
🇺🇸Teva Investigational Site 008, New Haven, Connecticut, United States
A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-04-29
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00203086
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 472
- Registration Number
- NCT00203034
- Locations
- 🇺🇸
Columbia - Presbyterian Medical Center, New York, New York, United States
🇺🇸Rush - Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸University of Rochester, Rochester, New York, United States
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 254
- Registration Number
- NCT00203164
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Long Island Jewish Medical Center, New Hyde Park, New York, United States
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 254
- Registration Number
- NCT00203177
- Locations
- 🇺🇸
Creighton University, Omaha, Nebraska, United States
🇺🇸Margolin Brain Institute, Fresno, California, United States
🇺🇸Rush - Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00203073
A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT00203125
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
- Conditions
- Relapse Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00203112